Cannabinoid Biotechnology

West, USA

30% Raised

Short Summary

Emerald Health Pharmaceuticals; a biotech company entering Phase 2 human studies with patented unique cannabinoid science & technology focused on diseases like multiple sclerosis and Parkinson's disease; 180+ yrs mgt-team experience; $16M raised.


Investment Raised
Previous Rounds N/A
Stage Other
Investor Role Silent


  • Team with decades of pharmaceutical, biotech and cannabinoid expertise
  • Unique cannabinoid-based new medicines; 15 issued int'l patents, 23 pending
  • Positive results from human phase 1 study for lead candidate, EHP-101
  • Raised US$16M through Regulation A+ financing to date
  • In 9 top medical journals showing preclinical efficacy in targeted diseases
Please note: Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. This platform is targeted solely at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. This information has not been approved as a financial promotion, and you must carry out your own due diligence.

Ask a question

Got a question about this project?

Sign up to view the full pitch

It's free to discover the next big thing

Already have an account?

Similar Projects

4% raised

Hemp Seed To Sale

location_on West, USA

We are a licensed full-service hemp processing and product formulation lab. 16,000 sq ft state of the art facility in "Peace Arch" Blaine WA. Looking for like-minded forward-thinking investor who knows the profound power of hemp and CBD.

US$ 1,500,000


US$ 100,000

Min per Investor

0% raised

Altering Helmet Design

location_on Midwest, USA

The patent-pending helmet design provides unseen safety features to a helmet user. The design utilizes a layered design technique to reduce strike forces hindering energy transfer to the user.

US$ 300,000


US$ 5,000

Min per Investor

0% raised

Spinal Cord Stimulation

location_on Midwest, USA

Minority shareholder in medical software company is poised to acquire it and merge with publicly traded spinal cord stimulation hardware company that had $48 million in sales revenue in 2018 and create new closed-loop spinal cord stimulation therapy

US$ 10,000,000


US$ 1,000,000

Min per Investor

load one similar proposal